| Quarterly Financials | Mar 2015 | Jun 2015 | Sept 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sept 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sept 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sept 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sept 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sept 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 |
Revenue  | 6,493 | 6,691 | 6,973 | 7,260 | 7,622 | 8,164 | 7,869 | 7,805 | 7,050 | 6,319 | 6,845 | 6,727 | 7,014 | 7,339 | 7,198 | 7,850 | 7,326 | 8,472 | 8,150 | 8,159 | 8,180 | 7,640 | 9,019 | 9,124 | 8,575 | 9,822 | 9,780 | 10,247 | 9,500 | 10,646 | 10,894 | 11,274 | 11,099 | 11,990 | 12,297 | 12,407 | 12,419 | 13,057 | 13,618 | 13,903 |
| Expenses | 5,318 | 5,679 | 5,000 | 4,877 | 5,382 | 5,335 | 5,092 | 5,472 | 5,590 | 6,064 | 5,275 | 5,200 | 5,294 | 5,618 | 6,621 | 5,587 | 6,147 | 6,379 | 6,334 | 6,314 | 7,083 | 9,375 | 6,360 | 6,431 | 7,147 | 7,529 | 6,996 | 7,257 | 11,042 | 7,877 | 7,996 | 8,237 | 8,300 | 8,932 | 9,013 | 8,974 | 9,049 | 9,045 | 9,352 | 9,983 |
| EBITDA | 1,175 | 1,012 | 1,973 | 2,383 | 2,240 | 2,829 | 2,776 | 2,333 | 1,460 | 255 | 1,570 | 1,528 | 1,720 | 1,721 | 577 | 2,263 | 1,179 | 2,094 | 1,816 | 1,845 | 1,098 | -1,736 | 2,659 | 2,693 | 1,427 | 2,293 | 2,784 | 2,990 | -1,542 | 2,769 | 2,899 | 3,037 | 2,799 | 3,058 | 3,284 | 3,433 | 3,370 | 4,012 | 4,266 | 3,920 |
| Operating Profit % | 13 % | 13 % | 27 % | 31 % | 27 % | 33 % | 34 % | 29 % | 18 % | 2 % | 20 % | 21 % | 21 % | 21 % | 3 % | 27 % | 13 % | 23 % | 20 % | 21 % | 12 % | -25 % | 25 % | 27 % | 16 % | 22 % | 27 % | 26 % | -18 % | 26 % | 26 % | 26 % | 23 % | 24 % | 25 % | 26 % | 23 % | 28 % | 29 % | 26 % |
| Depreciation | 462 | 240 | 258 | 251 | 288 | 316 | 304 | 307 | 338 | 347 | 359 | 339 | 455 | 402 | 427 | 471 | 454 | 457 | 473 | 547 | 575 | 496 | 499 | 532 | 554 | 503 | 530 | 554 | 557 | 588 | 610 | 660 | 672 | 651 | 633 | 622 | 650 | 655 | 626 | 631 |
| Interest | 135 | 135 | 158 | 128 | 103 | 135 | 54 | 167 | 45 | 109 | 157 | 95 | 155 | 131 | 130 | 145 | 150 | 104 | 84 | 63 | 52 | 52 | 33 | 26 | 30 | 35 | 36 | 19 | 37 | 14 | 19 | 46 | 93 | 81 | 49 | 35 | 74 | 62 | 69 | 52 |
| Profit Before Tax | 591 | 872 | 1,572 | 2,040 | 2,087 | 2,628 | 2,930 | 2,102 | 1,389 | -159 | 1,114 | 1,148 | 1,376 | 1,274 | 112 | 1,730 | 694 | 1,647 | 1,433 | 1,351 | 577 | -2,184 | 2,206 | 2,163 | 903 | 1,804 | 2,287 | 2,466 | -2,076 | 2,285 | 2,412 | 2,472 | 2,240 | 2,481 | 2,791 | 3,000 | 2,816 | 3,424 | 3,598 | 3,476 |
| Tax | -596 | 115 | 272 | 100 | 424 | 360 | 458 | 380 | 3 | 164 | 113 | 792 | -187 | 88 | 272 | 269 | -26 | 151 | 270 | 332 | 85 | 242 | 263 | 250 | 61 | 400 | 200 | 340 | 152 | 191 | 157 | 291 | 257 | 476 | 406 | 440 | 157 | 563 | 561 | 563 |
| Net Profit | 1,186 | 757 | 1,299 | 1,940 | 1,663 | 2,268 | 2,471 | 1,722 | 1,386 | -323 | 1,002 | 356 | 1,563 | 1,186 | -160 | 1,461 | 721 | 1,497 | 1,163 | 1,019 | 493 | -2,426 | 1,943 | 1,913 | 842 | 1,404 | 2,086 | 2,126 | -2,227 | 2,093 | 2,256 | 2,181 | 1,983 | 2,006 | 2,385 | 2,561 | 2,659 | 2,861 | 3,037 | 2,913 |
| EPS in ₹ | 3.70 | 2.30 | 4.30 | 6.40 | 5.90 | 8.50 | 9.30 | 6.10 | 5.20 | -1.77 | 3.80 | 1.34 | 5.60 | 4.41 | -1.12 | 5.18 | 2.65 | 5.78 | 4.43 | 3.81 | 1.67 | -6.90 | 7.56 | 7.72 | 3.70 | 6.00 | 8.50 | 8.60 | -9.50 | 8.60 | 9.40 | 9.00 | 8.30 | 8.40 | 9.90 | 10.50 | 11.10 | 11.80 | 12.70 | 12.10 |
Sun Pharmaceutical
1,764.75
-20.05
(-1.12%)
Market Cap
4,28,233.30 Cr
EPS
39.90
PE Ratio
35.92
Dividend Yield
0.76 %
Industry
Healthcare52 Week High
1,960.35
52 Week Low
1,377.20
PB Ratio
6.13
Debt to Equity
0.08
Sector
Pharmaceuticals
Live Chart 
Investment Returns
In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Analyst Rating
- By Refinitiv from31 analysts
Peer Comparison Compare Peers on Screener
| Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
| 1,764.75 | 4,28,233.30 | 35.92 | 49,887.20 | 12.06 | 9,648 | 13.77 | 61.58 | |
| 5,840.65 | 1,56,910.50 | 74.97 | 8,184.00 | 0.89 | 1,600 | 64.53 | 55.23 | |
| 1,511.20 | 1,23,084.40 | 24.45 | 26,520.70 | 14.17 | 4,155 | 47.38 | 60.28 | |
| 3,245.05 | 1,10,720.70 | 58.75 | 10,785.70 | 11.59 | 1,656 | 13.54 | 61.68 | |
| 1,177.90 | 1,00,988.70 | 18.34 | 28,905.40 | 12.36 | 5,578 | 1.69 | 51.86 | |
| 2,398.05 | 97,867.10 | 48.47 | 10,615.60 | 19.57 | 1,942 | -16.38 | 56.07 | |
| 2,068.75 | 96,711.60 | 32.93 | 20,141.50 | 19.94 | 1,936 | 38.82 | 54.50 | |
| 907.35 | 92,945.80 | 20.14 | 19,831.50 | 13.82 | 3,831 | 29.92 | 48.54 | |
| 1,194.95 | 70,253.80 | 19.68 | 29,559.20 | 17.55 | 3,169 | -10.04 | 61.05 | |
| 31,101.85 | 66,026.50 | 49.49 | 6,097.20 | 10.80 | 1,201 | 16.01 | 61.04 |
Growth Rate
Revenue Growth
12.06 %
Net Income Growth
12.70 %
Cash Flow Change
144.69 %
ROE
-0.35 %
ROCE
5.02 %
EBITDA Margin (Avg.)
4.46 %
Quarterly Financial Results
Balance Sheet
| Balance Sheet | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
| Total Assets | 49,028 | 55,530 | 61,410 | 64,516 | 64,694 | 68,253 | 67,667 | 69,808 | 80,744 | 85,463 |
| Fixed Assets | 12,683 | 15,872 | 17,675 | 18,853 | 21,837 | 22,847 | 21,553 | 22,665 | 24,065 | 23,211 |
| Current Assets | 29,122 | 29,941 | 32,954 | 31,636 | 31,069 | 31,654 | 30,442 | 34,865 | 39,862 | 43,433 |
| Capital Work in Progress | 2,039 | 2,175 | 2,801 | 2,465 | 1,411 | 1,220 | 1,567 | 1,287 | 4,973 | 5,354 |
| Investments | 2,117 | 1,830 | 1,192 | 7,143 | 7,903 | 10,143 | 9,612 | 12,849 | 14,824 | 15,026 |
| Other Assets | 32,189 | 35,653 | 39,742 | 36,056 | 33,544 | 34,042 | 34,935 | 33,007 | 36,881 | 41,872 |
| Total Liabilities | 49,028 | 55,530 | 61,410 | 64,516 | 64,694 | 68,253 | 67,667 | 69,808 | 80,744 | 85,463 |
| Current Liabilities | 16,353 | 13,144 | 17,887 | 19,864 | 17,340 | 15,706 | 16,146 | 17,208 | 19,906 | 16,984 |
| Non Current Liabilities | 4,186 | 5,319 | 3,093 | 2,454 | 2,632 | 3,421 | 2,041 | 1,533 | 1,522 | 1,373 |
| Total Equity | 28,489 | 37,068 | 40,431 | 42,198 | 44,723 | 49,125 | 49,480 | 51,066 | 59,316 | 67,106 |
| Reserve & Surplus | 25,383 | 32,741 | 36,400 | 38,074 | 41,169 | 45,025 | 46,223 | 47,771 | 55,755 | 63,427 |
| Share Capital | 207 | 241 | 240 | 240 | 240 | 240 | 240 | 240 | 240 | 240 |
Cash Flow
| Cash Flow | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
| Net Cash Flow | 2,927 | 848 | 611 | -736 | -844 | -1,386 | 596 | -1,765 | 116 | 4,662 |
| Investing Activities | -1,502 | -3,949 | -4,186 | -3,104 | -310 | -2,225 | 407 | -5,556 | -7,220 | -763 |
| Operating Activities | 5,616 | 6,686 | 7,082 | 3,907 | 2,196 | 6,555 | 6,170 | 8,985 | 4,959 | 12,135 |
| Financing Activities | -1,187 | -1,889 | -2,285 | -1,539 | -2,731 | -5,715 | -5,981 | -5,194 | 2,376 | -6,710 |
Share Holding
| % Holding | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 |
| Promoter | 54.48 % | 54.48 % | 54.48 % | 54.48 % | 54.48 % | 54.48 % | 54.48 % | 54.48 % | 54.48 % | 54.48 % | 54.48 % | 54.48 % | 54.48 % | 54.48 % | 54.48 % | 54.48 % |
| FIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 16.79 % | 0.00 % | 17.72 % | 17.23 % | 18.02 % | 18.05 % |
| DIIs | 21.59 % | 21.93 % | 21.67 % | 20.94 % | 19.94 % | 19.57 % | 18.60 % | 19.14 % | 19.24 % | 19.75 % | 19.67 % | 17.97 % | 18.83 % | 19.28 % | 18.61 % | 18.55 % |
| Government | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| Public / Retail | 7.34 % | 7.21 % | 6.79 % | 6.68 % | 6.49 % | 6.31 % | 5.91 % | 5.76 % | 5.70 % | 5.65 % | 5.56 % | 5.41 % | 5.44 % | 5.57 % | 5.43 % | 5.47 % |
| Others | 16.60 % | 16.38 % | 17.05 % | 17.90 % | 19.09 % | 19.64 % | 21.01 % | 20.63 % | 20.58 % | 20.12 % | 3.51 % | 22.13 % | 3.53 % | 3.44 % | 3.46 % | 3.46 % |
| No of Share Holders | 0 | 7,09,045 | 7,57,366 | 6,75,908 | 6,80,800 | 6,62,384 | 6,47,167 | 6,43,512 | 6,25,252 | 6,24,561 | 6,16,588 | 6,12,626 | 6,31,392 | 6,73,217 | 6,57,317 | 6,89,623 |
Dividend History
Dividends per share (FY)
Dividend yield (FY) %
| Annual Cash Flows | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Per Share (₹) | 0.00 | 3.5 | 2 | 2.75 | 4 | 7.5 | 10 | 11.5 | 13.5 | 0.00 |
| Dividend Yield (%) | 0.00 | 0.71 | 0.42 | 0.78 | 0.67 | 0.82 | 1.01 | 0.71 | 0.76 | 0.00 |
Corporate Action
Login to View
This information is available only for users of ScanX and Dhan.To proceed ahead,
LoginOpen Account
Announcements
Closure of Trading Window
Announcement under Regulation 30 (LODR)-Updates on Acquisition
Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011.
Announcement under Regulation 30 (LODR)-Updates on Acquisition
Announcement under Regulation 30 (LODR)-Acquisition
Announcement under Regulation 30 (LODR)-Investor Presentation
Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011.
Shareholder Meeting / Postal Ballot-Notice of Postal Ballot
Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011.
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 - Regulatory Order
Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 - Regulatory Order
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Sustainability Report For The Financial Year 2023-24
Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 - Appointment Of Chief Operating Officer
Q3FY25 Investor Call Audio Recording
Integrated Filing (Financial)
Corporate Action-Board approves Dividend
Outcome Of The Board Meeting Held Today I.E. January 31 2025
Shareholder Meeting / Postal Ballot-Outcome of Court Convened Meeting
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Intimation Under Regulation 42 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 - Revision In Record Date
Corporate Action-Board to consider Dividend
Board Meeting Intimation for Approval Of Financial Results For Quarter And Nine Months Ended December 31 2024 And Interim Dividend
Announcement under Regulation 30 (LODR)-Acquisition
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018
Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 - Sale Of Subsidiary
Announcement under Regulation 30 (LODR)-Newspaper Publication
Notice Of The National Company Law Tribunal Convened Meeting Of Equity Shareholders On January 21, 2025
Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 - Regulatory Order
Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 - Regulatory Order
Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 - Update On Regulatory Order
National Company Law Tribunal Convened Meeting Of Equity Shareholders Shall Be Held On Tuesday, January 21, 2025 At 3:00 P.M. IST By Video Conferencing.
Announcement under Regulation 30 (LODR)-Newspaper Publication
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Announcement under Regulation 30 (LODR)-Investor Presentation
Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 - Regulatory Order
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 - Regulatory Order
Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Disclosure under Regulation 30A of LODR
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 - Regulatory Order
Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 - Regulatory Order
Technical Indicators
RSI(14)
Neutral 61.58
ATR(14)
Less Volatile 39.22
STOCH(9,6)
Overbought 87.93
STOCH RSI(14)
Overbought 95.60
MACD(12,26)
Bullish 19.92
ADX(14)
Strong Trend 32.99
UO(9)
Bearish 56.98
ROC(12)
Uptrend But Slowing Down 9.34
WillR(14)
Neutral -20.70
About Sun Pharmaceutical
Sun Pharmaceutical Industries Limited is a global specialty generic pharmaceutical company based in India. It manufactures and markets a wide range of pharmaceutical formulations including generics, branded generics, complex products, over-the-counter drugs, and active pharmaceutical ingredients. The company has a diverse portfolio covering multiple therapeutic areas and dosage forms. Sun Pharma has a strong presence in India and the US, which account for about 70% of its revenue. It operates 43 manufacturing facilities worldwide and invests 7-8% of revenue in R&D annually. The company has expanded through acquisitions and licensing deals to strengthen its specialty and generic portfolios. Key specialty products include Ilumya, Winlevi, Cequa and others in dermatology, ophthalmology and oncology. Sun Pharma supplies medicines to over 100 countries and has manufacturing facilities across six continents.
Website
Chairperson NameDilip S Shanghvi
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
